ReeLabs

ReeLabs is India's integrated stem cell company, founded in 2009 by two MD pathologists and an IIT graduate. The company operates the largest state-of-the-art stem cell facility in Asia, located in Mumbai, with FDA, GLP, and GMP approvals. ReeLabs banks stem cells from ten biological sources: cord blood, cord tissue, placenta, amniotic sac, amniotic fluid, bone marrow, dental samples, adipose tissue, and menstrual blood. This multi-source capability is unique in India and enables personalized preservation of biological assets for future therapeutic use.

The company's service model spans from biobanking to clinical delivery of therapies. ReeLabs offers stem cell banking and preservation, advanced longevity and anti-aging treatments, therapeutic applications for conditions including leukemia, thalassemia, diabetes, and osteoarthritis, and biological age testing. Their proprietary Golden Vial program targets documented reversal of biological age. The company combines regenerative medicine research with clinical practice, having conducted seven FDA-approved clinical trials and published over 300 international scientific papers.

ReeLabs' approach centers on harnessing the body's own cellular potential for health optimization. Rather than relying on external interventions, the company develops protocols to isolate, expand, and apply stem cells for controlling degenerative conditions and age-related decline. Their science-first philosophy emphasizes personalized care plans tailored to individual medical history, with a stated goal of reducing biological age by up to 20 years through measured, evidence-based cellular therapies.